KR20190112801A - Wnt 억제제 및 항-pd-1 항체 분자의 조합 투여 일정 - Google Patents

Wnt 억제제 및 항-pd-1 항체 분자의 조합 투여 일정 Download PDF

Info

Publication number
KR20190112801A
KR20190112801A KR1020197026087A KR20197026087A KR20190112801A KR 20190112801 A KR20190112801 A KR 20190112801A KR 1020197026087 A KR1020197026087 A KR 1020197026087A KR 20197026087 A KR20197026087 A KR 20197026087A KR 20190112801 A KR20190112801 A KR 20190112801A
Authority
KR
South Korea
Prior art keywords
ser
day
administered
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197026087A
Other languages
English (en)
Korean (ko)
Inventor
제이슨 러셀 돕슨
수잔 무디
마가렛 엘리스 맥러플린
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Priority to KR1020247000317A priority Critical patent/KR20240007717A/ko
Publication of KR20190112801A publication Critical patent/KR20190112801A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020197026087A 2017-02-14 2018-02-12 Wnt 억제제 및 항-pd-1 항체 분자의 조합 투여 일정 Ceased KR20190112801A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247000317A KR20240007717A (ko) 2017-02-14 2018-02-12 Wnt 억제제 및 항-pd-1 항체 분자의 조합 투여 일정

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762458640P 2017-02-14 2017-02-14
US62/458,640 2017-02-14
US201862616682P 2018-01-12 2018-01-12
US62/616,682 2018-01-12
PCT/IB2018/050846 WO2018150312A1 (en) 2017-02-14 2018-02-12 Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247000317A Division KR20240007717A (ko) 2017-02-14 2018-02-12 Wnt 억제제 및 항-pd-1 항체 분자의 조합 투여 일정

Publications (1)

Publication Number Publication Date
KR20190112801A true KR20190112801A (ko) 2019-10-07

Family

ID=61526841

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197026087A Ceased KR20190112801A (ko) 2017-02-14 2018-02-12 Wnt 억제제 및 항-pd-1 항체 분자의 조합 투여 일정
KR1020247000317A Ceased KR20240007717A (ko) 2017-02-14 2018-02-12 Wnt 억제제 및 항-pd-1 항체 분자의 조합 투여 일정

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247000317A Ceased KR20240007717A (ko) 2017-02-14 2018-02-12 Wnt 억제제 및 항-pd-1 항체 분자의 조합 투여 일정

Country Status (12)

Country Link
US (2) US11406633B2 (enExample)
EP (1) EP3582811B1 (enExample)
JP (3) JP2020506159A (enExample)
KR (2) KR20190112801A (enExample)
CN (2) CN110267682A (enExample)
AU (1) AU2018221557C1 (enExample)
CA (1) CA3051989A1 (enExample)
IL (1) IL268341B2 (enExample)
MX (1) MX2019009630A (enExample)
RU (1) RU2767533C2 (enExample)
TW (1) TWI771372B (enExample)
WO (1) WO2018150312A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
EP3389712B1 (en) * 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
JP7451506B2 (ja) * 2018-09-27 2024-03-18 ムスク・ファウンデイション・フォー・リサーチ・ディベロップメント がんの治療用の薬学的組合せ
WO2020236078A1 (en) * 2019-05-22 2020-11-26 Agency For Science, Technology And Research Pharmaceutical combination
CN113134090B (zh) * 2021-03-26 2022-05-17 武汉大学中南医院 一种抗肿瘤药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
US20160303137A1 (en) * 2015-04-20 2016-10-20 Indiana University Research And Technology Corporation Dual pi3k and wnt pathway inhibition as a treatment for cancer
CN104767366A (zh) * 2015-04-21 2015-07-08 永济新时速电机电器有限责任公司 辅助变流器和车辆
CA2985818A1 (en) * 2015-05-31 2016-12-08 Curegenix Corporation Combination compositions comprising an antagonist of porcupine and a pd-l/pd-1 axis antagonist for immunotherapy

Also Published As

Publication number Publication date
CA3051989A1 (en) 2018-08-23
US11406633B2 (en) 2022-08-09
TW201836610A (zh) 2018-10-16
EP3582811A1 (en) 2019-12-25
US20230063366A1 (en) 2023-03-02
CN117752784A (zh) 2024-03-26
AU2018221557A1 (en) 2019-08-15
IL268341B2 (en) 2023-06-01
EP3582811B1 (en) 2024-07-10
IL268341A (en) 2019-09-26
US20190365746A1 (en) 2019-12-05
CN110267682A (zh) 2019-09-20
AU2018221557C1 (en) 2021-10-14
JP2022174157A (ja) 2022-11-22
RU2019128843A3 (enExample) 2021-05-17
TWI771372B (zh) 2022-07-21
KR20240007717A (ko) 2024-01-16
WO2018150312A1 (en) 2018-08-23
AU2018221557B2 (en) 2021-03-11
RU2767533C2 (ru) 2022-03-17
RU2019128843A (ru) 2021-03-16
JP2020506159A (ja) 2020-02-27
MX2019009630A (es) 2019-11-08
JP2024133495A (ja) 2024-10-02

Similar Documents

Publication Publication Date Title
KR102606252B1 (ko) 항-pd-1 항체로 암을 치료하는 방법
JP6767362B2 (ja) リンパ球における阻害経路の中和
EP3344658B1 (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
EP3423495B1 (en) Antibodies specific to human poliovirus receptor (pvr)
JP6840127B2 (ja) がんの治療における抗ｐｄ−１抗体および抗ｍ−ｃｓｆ抗体の併用
KR20190112801A (ko) Wnt 억제제 및 항-pd-1 항체 분자의 조합 투여 일정
AU2016298823A1 (en) Combination of PD-1 antagonist with an EGFR inhibitor
CN109563170A (zh) 抗gitr抗体及其用途
KR20190017767A (ko) C-raf 억제제의 치료적 용도
US20230042258A1 (en) Anti-il-27 antibodies and uses thereof
US12358978B2 (en) Anti-IL-27 antibodies and uses thereof
TW202216778A (zh) Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
KR20220066346A (ko) 항-il-27 항체 및 이의 용도
KR20200134253A (ko) 약제학적 병용물
KR20190107719A (ko) 세리티닙 및 항-pd-1 항체 분자의 조합물에 대한 투여 일정
JP7712496B2 (ja) 抗ｃｄ３９抗体及びその使用
KR20230004635A (ko) Csf-1r에 의해 조절되는 질병을 치료하기 위한 투여 요법
HK40011167A (en) Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination
HK40011167B (en) Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination
HK40001896A (en) Antibodies specific to human poliovirus receptor (pvr)
HK40001896B (en) Antibodies specific to human poliovirus receptor (pvr)
HK1252860B (zh) 用於在淋巴瘤或白血病中诱导淋巴细胞增多的针对人csf-1r的抗体
HK1247848B (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190905

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210209

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230501

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231004

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230501

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I